Clinical Trials Browser

Recruiting × OTHER × SMARCB1-Deficient Malignancies × Clear all

NCT06444880 2026-01-08

Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

Phase 2 Recruiting

SMARCB1-Deficient Malignancies